JW-1-283 inhibits melanoma tumor growth via stabilization of the p53 pathway  

作　　者：Yang Xie Ruida Hou Kelli LHartman Jianxiong Jiang Zhongzhi Wu Wei Li 

机构地区：[1]Drug Discovery Center,College of Pharmacy,University of Tennessee Health Science Center,Memphis,TN38163,USA

出　　处：《Genes & Diseases》2024年第3期18-21,共4页基因与疾病（英文）

基　　金：supported by National Institutes of Health(NIH)grant R01CA240447 to W.L.

摘　　要：Melanoma is a lethal skin malignancy and the fifth most diagnosed cancer in the United States.1 Currently,for unresectable melanoma,the recommended treatment options include checkpoint inhibitor immunotherapy targeting programmed cell death 1(PD-1),and inhibitors targeting the mitogen-activated protein kinase(MAPK)pathway.However,the response rate may vary among the patients,and therefore demanding the development of novel treatment strategies.Tumor suppressor TP53has been suggested as one of the critical regulators mediating the aggressiveness and progression of melanoma.

关 键 词：MELANOMA SUPPRESSOR DEATH 

分 类 号：R739.5[医药卫生—肿瘤]